TENX

Tenax Therapeutics Stock Price

1.06
-0.05 (-4.5%)
Upgrade to Real-Time
Afterhours (Closed)
1.06
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Tenax Therapeutics Inc TENX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.05 -4.5% 1.06 19:59:36
Close Price Low Price High Price Open Price Previous Close
1.06 1.05 1.11 1.11 1.11
Bid Price Ask Price Spread News
1.06 1.28 0.22 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
135 43,821 $ 1.07 $ 46,779 186,503 0.25 - 2.90
Last Trade Time Type Quantity Stock Price Currency
16:00:00 159 $ 1.06 USD

Tenax Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 13.38M 12.62M 12.58M $ - $ - -1.36 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Tenax Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TENX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.191.201.051.1346,214-0.13-10.92%
1 Month1.381.431.051.28134,826-0.32-23.19%
3 Months1.251.981.051.48193,759-0.19-15.2%
6 Months0.6452.900.601.47755,3210.41564.34%
1 Year1.242.900.251.39433,478-0.18-14.52%
3 Years9.19412.630.252.68379,889-8.13-88.47%
5 Years60.00268.000.258.61375,505-58.94-98.23%

Tenax Therapeutics Description

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.


Your Recent History
NASDAQ
TENX
Tenax Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.